Information Provided By: 
Fly News Breaks for January 18, 2019
LJPC
Jan 18, 2019 | 09:27 EDT
SunTrust analyst Joon Lee lowered his price target on La Jolla to $20, citing a slower than anticipated launch of its "highly differentiated drug, Giapreza, launched in March 2018 for septic or distributive shock." Despite the company's disappointing Q2 and Q3 outlook, the analyst is keeping his Buy rating on the shares, noting that he may be proven "overly conservative" in tempering the forecast for this "significant value-add in the care of critically ill patients with few or no other options."
News For LJPC From the Last 2 Days
There are no results for your query LJPC
